Ancer Rectal News Today

Long-term data from the OPRA trial show organ preservation at 5 years in about half of patients with stage II/III rectal adenocarcinoma who received total neoadjuvant therapy.

A marked reduction in colorectal cancer recurrence after surgery has led investigators to wonder whether some patients can skip intensive surveillance afterward.

With organ preservation on the rise, investigators say practice guidelines need to catch up.

After recovering from COVID-19, a woman was discovered unconscious at her workplace, triggering a series of events culminating in an unforeseen diagnosis.

Maybe one of your patients can join a new clinical trial in colorectal cancer.

Investigators reported that the Immunoscore biopsy, which quantifies immune cell tumor infiltration, is a strong predictor of recurrence during watchful waiting for rectal cancer.

This is the second drug to receive a labeling update under the agencys Project Renewal program, which aims to keep labels of older cancer drugs up to date with current practice.

The guidance contradicts recommendations from other groups that lowered the starting age to 45.

Waiting more than 12 weeks for surgery following neoadjuvant therapy was associated with improved tumor regression grade and reduced risk of systemic recurrence but not overall survival.

Neoadjuvant chemoradiotherapy can be omitted in low-risk rectal cancer patients without compromising outcomes, but intensified in high-risk patients, new findings suggest.